24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
Fax: (361)578-5500

Medical Disorders
Basic InformationLookupsLatest News
COVID Can Tear Through a Household: CDCU.S Coronavirus Cases Top 9 MIllionGrocery Workers at Greater Risk for COVID Without SymptomsWhat You Need to Know About the Search for a COVID VaccineNearly 1 in 5 COVID-19 Patients May Still Carry VirusTired, Anxious, Overweight: How Lockdowns May Have Harmed Your HealthEli Lilly Antibody Drug Could Prevent COVID Hospitalizations: StudyDeath Rates Are Dropping for New Yorkers With COVID-19 -- Why?Asymptomatic Kids With COVID-19 May Also Carry Less VirusYour Guide to Getting a COVID-19 TestFauci Calls for National Mask MandateSmog Could Increase COVID-19 Deaths by 15% WorldwidePatients With Worst COVID-19 May Be Best Plasma Donors: StudyWill Expelled Droplets Spread COVID? Ventilation May Be KeyPeople With Down Syndrome Face Higher Risk of Severe COVID-19Loss of Smell More Common in COVID-19 Than ThoughtPsoriasis Meds Don't Raise Risk of Severe COVID-19: StudyTrial of Antibody Drug for COVID-19 Stopped for Lack of EffectivenessKnee or Hip Replacements Cut People's Risk for Falls: StudyWhat Will It Take for People to Embrace a COVID Vaccine?Kidney Trouble Greatly Raises Odds for Fatal COVID-19More Evidence Masks Slow COVID's SpreadDangerous COVID-19 Syndrome First Seen in Kids Also Strikes AdultsFading Sense of Smell Could Signal Higher Death Risk in Older AdultsHospitals Straining Under Weight of Surging COVID Case CountsU.S. Daily COVID-19 Case Count Sets New Record for the PandemicAn Unexpected Finding on What Might Drive Joint DiseaseCoronavirus in a Cough: Tests Show Masks Stopping the SpreadU.S. Daily COVID Case Count Nears Record for PandemicCould Common Asthma Meds Weaken Bones?Mask Use by Americans Now Tops 90%, Poll FindsCOVID-19 More Common in Pregnant Hispanics Than Other Moms-to-Be: StudyMore Than Half of Americans Know Someone Infected or Ill With COVID: PollCDC Broadens Definition of 'Close Contact' in Tracing COVID InfectionsAHA News: The Mummies' Message: Take Steps Against Heart DiseasePancreas Cells That Drive Type 1 Diabetes Appear in Healthy People, TooOne Big Reason Women May Be Less Prone to COVID-19New Wave of COVID Infections Taking Hold in AmericaSmog Tied to Raised Risk for Parkinson's, Alzheimer's DiseaseWhat Will Convince Americans to Get a COVID-19 Vaccine?Curbing COVID Brought Unexpected Benefit for Asthma Patients1 in 3 Americans With Arthritis Say Pain, Symptoms PersistCDC Recommends Face Masks in All Public Transportation SettingsIn Medieval Times, Plagues 'Sped Up' With Each New OutbreakWhat You Need to Know About Your Colon Cancer RiskNewer Rheumatoid Arthritis Drug May Help Ease Tough-to-Treat CasesCelebrate Autumn Traditions Without Raising Your COVID RiskNew Drug Could Extend Life for People With ALSHeart Defects Don't Increase Risk of Severe COVID-19Chinese COVID Vaccine Shows Promise in Early Trial
Questions and AnswersLinks
Related Topics


Early Trial Offers New Hope for People With Hemophilia

HealthDay News
by By Amy NortonHealthDay Reporter
Updated: Sep 9th 2020

new article illustration

WEDNESDAY, Sept. 9, 2020 (HealthDay News) -- Researchers may have found a way for people with severe hemophilia to take their standard treatment less often, if the results of an early trial pan out.

In what experts called a feat of bioengineering, scientists were able to create a "fusion protein" that may extend the interval between treatments for hemophilia -- from about every couple of days to once a week.

The early findings are based on a one-time treatment given to 16 patients.

But researchers were hopeful a larger, ongoing trial will prove the approach effective.

Hemophilia is a bleeding disorder caused by a genetic mutation. In the most common form -- hemophilia A -- people lack a properly functioning factor VIII, a protein that helps blood clot. Some people have relatively mild hemophilia -- with excessive bleeding if they sustain a cut, for example. Others have frequent spontaneous bleeding episodes into their joints and muscles.

When hemophilia is that severe, it requires regular treatment to prevent bleeding. Most often, that means infusions of lab-created factor VIII.

That factor VIII activity only lasts so long, however. So patients generally need infusions two or three times a week, explained Dr. Barbara Konkle, the lead researcher on the new trial.

Managing that regimen in daily life can be challenging, Konkle said, particularly when it's a child with hemophilia.

"Anything you can do to reduce the number of treatments will probably improve patients' quality of life," said Konkle, who is associate chief scientific officer at the nonprofit Bloodworks Northwest, in Seattle.

Her team looked at whether the new fusion protein -- dubbed BIVV001 -- can make for a longer-acting factor VIII.

The researchers recruited 16 men with severe hemophilia who were already on factor VIII treatment. (The disease primarily affects males.) Each patient was given an injection of factor VIII into a vein, followed by an injection of BIVV001.

Overall, the study found, the fusion protein extended the half-life of factor VIII by three to four times. On day 7, patients' factor VIII activity was still at a level considered high enough to prevent bleeding episodes.

It all suggests the approach could allow treatment to be weekly -- or possibly even every 10 days, said Dr. Pier Mannucci, of IRCCS Maggiore Policlinico Hospital in Milan, Italy.

To Mannucci, who wrote an editorial published with the study, the findings represent "more amazing progress" in treating hemophilia.

He pointed to key developments in recent years -- including promising findings on gene therapy, which might provide a cure to at least some people with hemophilia.

And already, patients have options other than factor VIII replacement. In 2017, the U.S. Food and Drug Administration approved a drug called emicizumab -- a lab-engineered antibody that mimics the activity of factor VIII.

Emicizumab has the advantage of being taken weekly, or even less often, and it's injected under the skin rather than into a vein, Mannucci pointed out.

But, he said, the drug lacks some benefits of an "authentic" factor VIII -- including the ability to treat sudden bleeding. So a longer-acting factor VIII could be an alternative to emicizumab, Mannucci said.

An ongoing "phase 3" trial is testing the new factor VIII product over the longer term, with patients receiving weekly doses.

Konkle said no safety issues emerged in this early study, published in the Sept. 10 New England Journal of Medicine. But the longer-term trial is needed to see whether any adverse effects, like allergic reactions, turn up.

Drugmakers Sanofi and Sobi, which are funding the research, developed BIVV001 together.

"It's really an incredible feat of bioengineering," Konkle said.

Historically, she explained, it's been difficult to create a longer-acting factor VIII. That's because the replacement protein interacts with a natural blood protein -- called von Willebrand factor -- which limits its half-life.

BIVV001, Konkle said, essentially "uncouples" the factor VIII replacement from von Willebrand factor circulating in patients' blood.

She believes the new therapy, if approved, "will be a really important addition to our treatment options."

But, Konkle added, "different approaches will be right for different patients."

No one knows what the new factor VIII therapy could cost. But on the whole, hemophilia treatments are highly expensive, according to the American Society of Hematology -- in the range of $300,000 to $500,000 a year.

More information

The U.S. Centers for Disease Control and Prevention has more on hemophilia treatment.